Universidad Peruana Cayetano Heredia
Quick facts
Marketed products
- "Raltegravir" and "Zidovudine" · Infectious Disease / Virology
Raltegravir is an integrase inhibitor that blocks HIV integration into host DNA, while zidovudine is a nucleoside reverse transcriptase inhibitor that prevents HIV RNA conversion to DNA.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Universidad Peruana Cayetano Heredia portfolio CI brief
- Universidad Peruana Cayetano Heredia pipeline updates RSS
Frequently asked questions about Universidad Peruana Cayetano Heredia
What are Universidad Peruana Cayetano Heredia's marketed drugs?
Top marketed products include "Raltegravir" and "Zidovudine".
Related
- "Raltegravir" and "Zidovudine" · Infectious Disease / Virology
- Sector hub: All tracked pharma companies